Deutsche Bank AG Takes $193.16 Million Position in Biogen Inc. $BIIB

Deutsche Bank AG acquired a new stake in Biogen Inc. (NASDAQ:BIIB) during the second quarter, Holdings Channel reports. The fund acquired 894,035 shares of the biotechnology company’s stock, valued at approximately $193,165,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Rothschild Investment LLC increased its stake in Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 56 shares during the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after purchasing an additional 57 shares during the last quarter. Kera Capital Partners Inc. lifted its stake in shares of Biogen by 3.5% in the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 58 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after purchasing an additional 65 shares during the period. Finally, Itau Unibanco Holding S.A. increased its position in shares of Biogen by 24.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 66 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Price Performance

BIIB opened at $212.55 on Wednesday. The stock’s 50-day moving average price is $204.36 and its 200 day moving average price is $193.76. Biogen Inc. has a 12-month low of $131.52 and a 12-month high of $219.72. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm has a market cap of $31.40 billion, a price-to-earnings ratio of 37.62, a PEG ratio of 6.48 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.Biogen’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the business posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts expect that Biogen Inc. will post 12.39 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on BIIB. Jefferies Financial Group restated a “buy” rating on shares of Biogen in a report on Monday, July 13th. Zacks Research raised shares of Biogen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Wedbush lifted their price target on shares of Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, July 30th. Needham & Company LLC boosted their price target on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, The Goldman Sachs Group upped their price objective on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $227.07.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.